Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HBM HoldingsFRA:6XY 64 PE Ratio (TTM) is 12.79 as of Jul. 30, 2026, which is 1% below its 10-year median of 12.97. GuruFocus rates FRA:6XY with a GF Score™ of 64/100 and a GF Value™ of €0.74 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 270 Biotechnology companies, HBM Holdings ranks better than 74.44% on this metric.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-07-30), HBM Holdings's share price is
€1.33.
HBM Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.10. Therefore, HBM Holdings's PE Ratio (TTM) for today is 12.79.
The historical rank and industry rank for HBM Holdings's PE Ratio (TTM) or its related term are showing as below:
FRA:6XY'
s PE Ratio (TTM) Range Over the Past 10 Years
Min: 4.33 Med: 12.97 Max: 611.79
Current: 12.93
During the past 8 years, the highest PE Ratio (TTM) of HBM Holdings was 611.79. The lowest was 4.33. And the median was 12.97.
FRA:6XY's PE Ratio (TTM) is ranked better than 74.44% of 270
companies
in the Biotechnology industry
Industry Median: 26.59
vs FRA:6XY: 12.93
During the past 8 years, HBM Holdings's highest 3-Year average EPS without NRI Growth Rate was -26.40% per year. The lowest was -61.50% per year. And the median was -43.95% per year.
HBM Holdings's EPS (Basic) for the
six
months ended in Dec. 2025 was €0.03.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.10.
HBM Holdings (FRA:6XY) PE Ratio (TTM) Explanation
The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.
If a company loses money, the PE Ratio (TTM) becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.
Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .
PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).
HBM Holdings PE Ratio (TTM) Related Terms
HBM Holdings PE Ratio (TTM) Historical Data
* Premium members only.
The historical data trend for HBM Holdings's PE Ratio (TTM) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:6XY vs VRTX, REGN, RVMD: PE Ratio (TTM) Comparison
For the Biotechnology subindustry, HBM Holdings's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HBM Holdings PE Ratio (TTM) vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HBM Holdings's PE Ratio (TTM) distribution charts can be found below:
* The bar in red indicates where HBM Holdings's PE Ratio (TTM) falls into.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
HBM Holdings's PE Ratio (TTM) for today is calculated as
HBM Holdings's Share Price of today is €1.33.
For company reported semi-annually, HBM Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.10.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
HBM Holdings (FRA:6XY) has a PE Ratio (TTM) of 12.79 as of Jul. 30, 2026. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on HBM Holdings and its competitors. This is near median its historical median of 12.97. Over the past decade, HBM Holdings' PE Ratio (TTM) has ranged from 4.33 to 611.79. According to the industry distribution chart, HBM Holdings ranks #69 out of 270 companies in the Biotechnology industry, placing it in the top 25.6%.
Is HBM Holdings' PE Ratio (TTM) too high?
HBM Holdings' current PE Ratio (TTM) of 12.79 is near median its 10-year median of 12.97. Over the past 10 years, this metric has ranged from a low of 4.33 to a high of 611.79. The Biotechnology industry median PE Ratio (TTM) is 26.59. HBM Holdings' value of 12.79 is 51.9% below this industry median. Based on the distribution chart, HBM Holdings ranks #69 out of 270 companies in the Biotechnology industry, which is above the industry midpoint. Overall, HBM Holdings has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does HBM Holdings' PE Ratio (TTM) compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HBM Holdings ranks #69 out of 270 companies for PE Ratio (TTM). This puts HBM Holdings in the upper half of its industry. The industry median PE Ratio (TTM) is 26.59. HBM Holdings' value of 12.79 is 51.9% below this benchmark. Historically, HBM Holdings' own PE Ratio (TTM) has ranged from 4.33 to 611.79 over the past decade. While the company's 10-year median is 12.97 vs. the industry median of 26.59, HBM Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio (TTM) for a Biotechnology company?
The median PE Ratio (TTM) among Biotechnology companies is 26.59, based on 270 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio (TTM) significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HBM Holdings's current PE Ratio (TTM) of 12.79 is 51.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio (TTM) mean?
A high PE Ratio (TTM) can signal that a stock is expensive relative to its fundamentals. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on HBM Holdings and its competitors. For the Biotechnology industry, the median PE Ratio (TTM) is 26.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HBM Holdings's current PE Ratio (TTM) is 12.79, which is near median its own 10-year median of 12.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HBM Holdings stock overvalued right now?
Based on GuruFocus' analysis, HBM Holdings (FRA:6XY) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.74, compared to a current price of €1.33 — trading 79.7% above its estimated fair value. The current PE Ratio (TTM) is 12.79, which is near median its 10-year median of 12.97 and 51.9% below the Biotechnology industry median of 26.59. HBM Holdings' overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio (TTM) calculated?
PE Ratio (TTM) is calculated from a company's financial statements. For HBM Holdings (FRA:6XY), the current PE Ratio (TTM) is 12.79 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HBM Holdings (FRA:6XY) Overvalued in 2026?
Based on GuruFocus' analysis, HBM Holdings stock appears to be overvalued.
The current stock price of €1.33 is trading 79.7% above its estimated GF Value™ of €0.74.
GuruFocus considers HBM Holdings to be Significantly Overvalued.
Key valuation signals for FRA:6XY:
PE Ratio (TTM): 12.79 (near median its 10-year median of 12.97)
GF Value™: €0.74 vs. price of €1.33 (79.7% above fair value)
Industry Position: 51.9% below the Biotechnology median (#69 of 270)
No single metric tells the full story. See the FRA:6XY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the Europe.
64GF Score
Get the complete analysis for FRA:6XY
PE Ratio (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6XY has been successfully added to your 
